According to the American Association for the Study of Liver Diseases (AASLD) treatment guidelines for hepatocellular carcinoma (HCC), the role of surgery has been expanded beyond the Barcelona Clinic Liver Cancer (BCLC) algorithm. We compared primary hepatectomy (PH) with transarterial chemoembolization (TACE) 
H epatocellular carcinoma (HCC) is the thirdleading cause of cancer deaths, resulting in approximately 750,000 deaths globally per annum.
(1) Despite recent improvements in surgical treatment, liver transplantation (LT), percutaneous ablation, hepatic resection, transarterial chemoembolization (TACE), and molecularly targeted therapies, the prognosis of HCC remains poor. The current practice guidelines for the management of HCC from the European Association for the Study of the Liver (EASL) and previous guidelines from the American Association for the Study of Liver Diseases (AASLD) recommend the Barcelona Clinic Liver Cancer (BCLC) staging system for prognostic prediction and treatment allocation. (2, 3) According to this algorithm, patients with intermediate-stage HCC (BCLC stage B; large/multifocal HCC, but in absence of portal thrombosis or extrahepatic disease, Child-Turcotte-Pugh [CTP] A or B, and performance status [PS] 0) and advanced-stage HCC (BCLC stage C; vascular invasion or extrahepatic spread, CTP A or B, and PS 1-2), primary hepatectomy (PH) is not the optimal treatment option. Instead, PH is limited to patients harboring very-early-or early-stage tumors (BCLC 0-A; solitary tumors or multinodular tumors with 3 nodules and size 3 cm with no vascular invasion or extrahepatic spread, CTP A or B, and PS 0) and in patients without portal hypertension or increased bilirubin levels.
Nonetheless, East-Asian countries, which account for more than 50% of the world-wide HCC prevalence, recommend PH for a broader spectrum of HCC patients. According to the seminars for the Asian Pacific Association for the Study of the Liver (APASL), (4) the American Hepato-Pancreato-Biliary Association (AHBPA), (5) the Korean Liver Cancer Study Group (KLCSG), (6) and the Japan Society of Hepatology (JSH), (7) the benefits of PH have been accepted for selected patients with multiple, large, or macrovascular invasive HCC when the patient's preoperative liver function is tolerable and postoperative residual liver is expected to function well. Furthermore, based on the recent BRIDGE and ITA.LI.CA databases, the vast majority (i.e., over two thirds) of nonideal candidates who did not meet the Western guidelines for resection underwent PH in numerous tertiary referral surgical centers and reported remarkable short-or long-term survival outcomes in comparison to modalities other than surgical resection. (8, 9) In order to reduce the enormous gap between clinical guidelines and real-world practice, the result from the first randomized controlled trial (RCT) of PH versus TACE for BCLC stage B/C patients was published recently. (10) Yin et al. compared PH to TACE alone for cases exceeding the Milan criteria (solitary <5 cm or multinodular with 3 nodules and size 3 cm) and found PH to be superior after a 3-year followup (hazard ratio [HR] , 0.43; P < 0.001). (10) Moreover, the recent 2017 HCC management guideline from the AASLD does not adopt the BCLC treatment algorithm in its current form, and recognizes that the definition of operability/resectability varies and is heterogeneous. Thus, the guideline does not deny the role of PH in T1/T2-stage HCC patients. (11) Given this inconsistency between the available guidelines, growing evidence has shown the potential advantage of PH beyond BCLC 0-A patients, especially for those classified as BCLC stage B or BCLC stage C.
Given that there is only one RCT currently available, both the advantages and disadvantages of PH for these patient groups depend on the data derived from nonrandomized comparative trials (NRCTs). Welldesigned NRCTs are not necessarily more biased than RCTs, given that NRCTs often have larger sample sizes and establish more solid evidence. (12) Thus, we conducted a systematic review and meta-analysis utilizing one RCT and high-quality nonrandomized studies to determine the comparative survival benefits of PH and TACE for the treatment of selected BCLC stage B or BCLC stage C HCC patients.
Materials and Methods

SEARCH STRATEGY
This meta-analysis was performed according to the guidelines and review protocols of the Preferred Reporting Items for Systematic Reviews and Metaanalysis (PRISMA) group. Two authors (M.H.H. and Y.-S.L.) independently performed a comprehensive systematic search for published articles using the PubMed, EMBASE, and Cochrane Library databases through to September 22, 2017 . Disagreement was resolved by discussion and consensus. The main keywords used for the search were "hepatocellular carcinoma," "HCC," "intermediate," "advanced," "BCLC B," "BCLC C," "hepatectomy," and "hepatic resection." The description of the search strategy is included in our evidence report (Supporting Table  S1 ). A bibliography of search results was reviewed manually to identify additional literature that was not indexed.
STUDY SELECTION, DATA EXTRACTION, AND QUALITY ASSESSMENT
Database searches were limited to full-text articles written in English. Two independent investigators (M.H.H. and Y.-S.L.) applied the inclusion and exclusion criteria (Supporting Table S2 ). The same two reviewers independently conducted data extraction and quality assessment. Retrieved data from the included studies, recorded using a predefined electronic spreadsheet, included: first author, year of publication, data source, country, study design, ethnicity, inclusion criteria, inclusion period, number of participants, participant and tumor characteristics, median survival time, HR, 1-, 3-, and 5-year survival rates, and procedure-related mortality. The Cochrane risk of bias was used to assess quality of the RCT. (13) The quality assessment for the included NRCTs was assessed based on the modified Methodological Index for Non-randomized Studies (MINORS) score. High-quality studies were selected having a total modified MINORS score 12, which is indicative of a low risk of bias. (14) The detailed items and fulfillment criteria are described in Supporting Table S3 . The discrepancies were resolved by consensus, and confirmed by another co-author (J.H.K.).
STUDY DEFINITIONS AND OUTCOMES OF INTEREST
We used the reported BCLC classification of the included trials if the BCLC stage was clearly demonstrated. Because some of the studies did not clearly report the patient's liver function or performance status, "out of Milan criteria" was defined as BCLC stage B/C and HCC with portal vein thrombosis (PVT) was defined as BCLC stage C.
The primary time-to-event outcomes were overall survival (OS) and 1-, 3-, and 5-year survival rates. The HRs and 95% confidence intervals (CIs) for OS were extracted directly based on data from multivariate Cox proportional hazard models in the included studies. If studies did not present survival data in the form of HRs and 95% CIs, described methods by Tierney et al. were used to calculate HRs from Kaplan-Meier curves. (15) Visual estimation of the 1-, 3-, and 5-year survival rates from Kaplan-Meier curves was performed, if the studies did not report odds ratios (ORs). Procedure-related mortality was defined as in-hospital mortality or 30-day mortality after each treatment.
STATISTICAL ANALYSIS
To reduce the bias attributable to the different follow-up periods and the timing of censored patients between the two treatment arms, OS in terms of log transformed HR and 95% CI was analyzed using an inverse variance model. The 1-, 3-, and 5-year survival rates and procedure-related mortalities were pooled in terms of OR and 95% CI utilizing the DersimonianLaird method. Between-study heterogeneity was calculated using Higgins' I 2 statistic. (16) A MantelHaenszel random-effects meta-analysis was performed for outcomes in consideration of interstudy heterogeneity. The 1-, 3-, and 5-year survival rates for PH and TACE are presented graphically using bubble plots generated using the metaprop command in STATA/ SE statistical software (version 15.0; StataCorp LP, College Station, TX), in which the size of the circles is proportional to the number of cases in each study. Because of the lack of RCTs, stratified two-step models were used. Pooled HRs and ORs were initially calculated for the RCT and propensity-score-matched (PSM) NRCTs. Furthermore, all NRCTs were included in the meta-analysis. Subgroup analyses were conducted based on BCLC stage and the proportion of baseline CTP A population in the included trials. Various sensitivity analyses along with extraction of 
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98/2 (25) baseline characteristics of included studies were also performed to reduce interstudy heterogeneity: (1) matched patient factors; (2) matched tumor factors; (3) matched patients and tumor factors; (4) hepatitis B virus (HBV; 80% of patients); (5) 3 tumor numbers dominant (80% of patients); (6) tumor thrombosis (100% of patients); (7) publication after 2015; and (8) Asians. To identify matched baseline factors, independent t tests and v 2 tests were used for dichotomous and continuous variables, respectively. To evaluate the effects of covariates on the pooled estimates and the heterogeneity across studies, metaregression analysis was conducted with covariates including publication year, study design, number of involved centers, number of patients, patients' mean age, proportion of males, mean alpha-fetoprotein (AFP) levels, proportion of CTP A class, mean tumor diameters, and proportion of single tumors. Publication bias was assessed visually using a funnel plot that displayed the studies in a plot of effect size against sample size, or statistically using Egger's regression model and Begg's funnel plot. The overall effect achieved statistical significance if the two-sided P value was <0.05. All statistical analyses were performed using STATA/SE statistical software (version 15.0; StataCorp LP). The study protocol was approved by the Institutional Review Board of the Korea University Guro Hospital (KUGH-16211). All authors had access to the study data and reviewed and approved the final manuscript.
Results
SEARCH AND STUDY SELECTION
An extensive bibliographical search strategy identified 17,740 articles after removing duplicates. Subsequently, as described in Supporting Fig. S1, 16 ,457 studies were removed after initial screening and a total of 409 unique records were evaluated for the full-text review. Of these, 382 studies did not fulfill the inclusion criteria. Among the remaining 27 studies, eight studies were reported from three identical institutions and shared overlapping periods and populations. Therefore, we chose the more recent and comprehensive data sets. (17) (18) (19) Additionally, four studies were excluded after quality assessment (modified MINORS score <12). The details and reasons for exclusion requiring consensus between the authors are described in Supporting Table S4 . Finally, 18 studies (10, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) reporting PH versus TACE in BCLC stage B or stage C patients were included in the systematic review and meta-analysis.
STUDY DEMOGRAPHICS AND QUALITY OF EVIDENCE
Eighteen trials (one RCT, five PSM NRCTs, and 12 NRCTs) (10, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) consisting of 20 data sets and a total of 5,986 patients were included in the metaanalysis. The RCT was a single-center trial conducted in China. (10) A further 17 NRCTs were performed in Spain (one NRCT), Korea (two NRCTs), China (three PSM NRCTs, seven NRCTs), Taiwan (one PSM NRCT, two NRCTs), and Japan (one PSM NRCT). Nine studies (17, 20, 21, 23, 27, 29, 30, 32, 33) with 3,457 patients included BCLC stage B patients, and another nine trials (11 data sets) (18, 19, 22, (24) (25) (26) 28, 30, 31) with 3,051 patients enrolled BCLC stage C patients. All trials were published between 2010 and 2017. Six trials were published before 2015. Most trials enrolled the Asian population except for one. (27) Among the included studies, 10 studies showed dominant HBV infection (80% of patients). The majority of enrolled patients were CTP class A ranging from 60% to 100%, and 12 trials showed a dominant CTP A population (80% of patients). Five studies showed mainly 3 numbers of tumor (80% of patients) even though tumor size or numbers varied between the trials. Baseline characteristics in 13 trials (one RCT, five PSM NRCTs, and seven NRCTs) were adequately matched for baseline patient factors (age, sex, and viral etiology) and tumor factors (AFP, CTP class, and tumor size or number). The detailed main findings for the included studies are summarized in Table 1 . The risk of bias for an RCT was low. (10) The results of the quality assessment of the RCT and all eligible NRCTs are shown in Supporting Tables S5 and S6, respectively.
EVIDENCE FROM PRIMARY OUTCOMES Overall Survival
The pooled analysis demonstrated that PH had significantly better OS than TACE in the RCT and PSM NRCTs (HR, 0.65; 95% CI, 0.53-0.78; P < 0.00001; I 2 5 86%) and in all studies (HR, 0.59; 95% CI, 0.51-0.67; P < 0.00001; I 2 5 84%) for BCLC stage B/C patients with a high level of heterogeneity (Fig. 1) . According to the BCLC stage, stage B patients showed significantly better OS after PH than after TACE in the PSM NRCTs and all studies had a high degree of heterogeneity (HR, 0.56; 95% CI, 0.35-0.90; P 5 0.02; I 2 5 not applicable; HR, 0.53; 95% CI, 0.43-0.65; P < 0.00001; I 2 5 77%, respectively). In addition, BCLC stage C patients also showed significantly better OS after PH compared to TACE in the PSM NRCTs and in all studies with a high grade of heterogeneity (HR, 0.72; 95% CI, 0.59-0.89; P 5 0.002; I 2 5 86%; HR, 0.67; 95% CI, 0.59-0.77; P < 0.00001; I 2 5 79%, respectively; Fig. 2 ). Figure 3 shows the pooled results of 1-, 3-, and 5-year survival rates for PH versus TACE. The pooled analysis demonstrated that the patients that underwent PH had higher 1-, 3-, and 5-year survival rates than TACE patients according to RCT 1 PSM NRCT (OR, 1.86; 95% CI, 1.45-2.38; P < 0.00001; I 2 5 40%; OR, 2.61; 95% CI, 1.81-3.76; P < 0.00001; I 2 5 66%; and OR, 2.20; 95% CI, 1.52-3.20; P < 0.0001; I 2 5 53%, respectively) and all studies (OR, 2.16; 95% CI, 1.66-2.81; P < 0.00001; I 2 5 75%; OR, 2.64; 95% CI, 2.03-3.45; P < 0.00001; I 2 5 71%; and OR, 2.71; 95% CI, 2.01-3.65; P < 0.00001; I 2 5 70%, respectively), albeit with some heterogeneity. Based on the BCLC stage, PH showed significantly higher 1-, 3-, and 5-year survival rates than TACE for all studies of BCLC stage B and stage C with high heterogeneity (all P 0.0001, I
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2 range from 51% to 85%). Figure 4 illustrates the mean 1-, 3-, and 5-year survival rates following PH and TACE. In BCLC stage   FIG. 2 . Pooled HR for OS according to BCLC stage B/C patients, the mean 1-, 3-, and 5-year survival rates after PH were 71%, 42%, and 33% and those of TACE were 54%, 24%, and 16%, respectively. As for BCLC stages, similar trends were observed in BCLC stage B patients (1-, 3-, and 5-year survival rates: PH vs. TACE; 84%, 57%, and 45% vs. 68%, 34%, and 23%, respectively) and BCLC stage C patients (1-, 3-, and 5-year survival rates: PH vs. TACE; 62%, 42%, and 20% vs. 45%, 16%, and 8%, respectively; Fig. 4 ).
Sensitivity Analysis and Subgroup Analysis
The sensitivity analyses for OS, and 1-, 3-, and 5-year survival rates are summarized in Table 2 . In BCLC stage B and stage C patients, sensitivity analysis including matched patient factors, matched tumor factors, matched patients and tumor factors, baseline HBV (80% of patients), 3 tumor numbers (80% of patients), tumor thrombosis (100% of patients), publication after 2015, and Asians showed an improvement in mortality after PH over TACE, consistent with evidence the from primary outcome analysis. In accord with the BCLC stage, both BCLC stage B and stage C patients showed significant benefit for PH over TACE. In particular, the results of overall effects for PH in BCLC stage C patients and in BCLC stage C with tumor thrombosis (100% proportion of patients) were similar (HR, 0.67; 95% CI, 0.59-0.77; P < 0.00001; I 2 5 79% vs. HR, 0.68; 95% CI, 0.59-0.78; P < 0.00001; I 2 5 79%, respectively). However, different sensitivity analyses for BCLC stage B/C patients and each BCLC stage did not decrease interstudy heterogeneity.
The subgroup analysis using a proportion of CTP A patients is shown in Fig. 5 . For BCLC stage B/C, the pooled results for the studies including a 100% proportion of CTP A patients (four data sets with 1,336 patients; HR, 0.50; 95% CI, 0.38-0.66; P < 0.00001) tended to more favor PH than those results for 80% proportion of CTP A patients and <80% proportion of CTP A patients (14 data sets with 4,201 patients; HR, 0.55; 95% CI, 0.46-0.65; P < 0.00001; six data sets with 1,785 patients; HR, 0.66; 95% CI, 0.52-0.83; P 5 0.001, respectively). These trends are also shown for BCLC stage B and stage C. Nonetheless, the survival benefits for PH over TACE are consistent across different BCLC stages or CTP A proportion (all P < 0.05).
Metaregression Analysis
Meta-regression analysis showed a trend for publication year, baseline mean age, baseline proportion of males, HBV, CTP A class, and single tumor, but the trend was not statistically significant (for all P > 0.05; Fig. 6 ). Given the significant heterogeneity in the overall effect estimates, the contribution of different study characteristics to the level of heterogeneity was calculated (Supporting Table S7 ). No significant factors contributed to the level of heterogeneity, and proportion of heterogeneity ranged from -8.54% to 14.84% (for all covariates, P > 0.05). The remaining heterogeneity was small (s 2 range from 0.0734 to 0.1155). The metaregression analysis categorized by BCLC stage was not achieved and was attributed to the lack of data in the included study.
Procedure-Related Mortality and Publication Bias
Procedure-related mortality was not statistically different between the two treatment modalities in BCLC stage B plus stage C patients (OR, 1.27; 95% CI, 0.70-2.30; P 5 0.439; I 2 5 0%; Supporting Fig. S2 ). The funnel plots of OS and 1-, 3-, and 5-year survival outcomes for PH and TACE are shown in Supporting Fig. S3 . However, no significant asymmetry of the funnel plots was detected (all Begg's and Egger's P value, >0.05). burden, liver function, and prognostic prediction and its association with a treatment algorithm for five different HCC stages (BCLC 0, A, B, C, and D). (2, 3) The management algorithm suggests that intermediate-stage (BCLC B) patients be treated only by TACE. (2, 3) Given treatment, patient survival is expected to be prolonged compared to that in untreated patients (1-year survival rate: TACE vs. controls, 82% vs. 63%). (34) In contrast, advanced-stage (BCLC C) patients would be optimal candidates for sorafenib treatment with higher survival benefits compared to conservative care (1-year survival rate; sorafenib vs. controls; 44% vs. 33%). (34) However, there has been criticism that the BCLC treatment algorithm may not reflect cancer progression or prognosis because the classification is based on the analysis of a cohort of 77 early and 102 intermediate or advanced HCC patients dating back to 1999. (35) In addition, the staging system analyzed predominantly hepatitis C virus (HCV)-associated HCC with impaired liver function and cirrhosis, which may not reflect other predominant etiologies such as HBV-associated HCC.
In the past, primary surgical resection was not the preferred treatment option for patients with intermediate (BCLC stage B) to advanced (BCLC stage C) HCC owing to increased surgical complications, subsequent liver decompensation, and tumor recurrence rates. (2, 3) Nevertheless, there have been recent improvements in the understanding of HCC along with advances in surgical techniques that reduce perioperative morbidity and mortality. A recent single-arm systematic review of 50 studies including 14,808 patients with large (5 cm) or multinodular HCC showed favorable 1-and 5-year survival rates for hepatic resection (81% and 42%). (36) Additionally, data from 24 studies including a total of 4,389 patients with major vascular invasion reported encouraging 1-and 5-year survival rates for surgical resection (50% and 18%). (36) To date, rapidly growing evidence suggests that more aggressive surgical resection is feasible and may provide survival benefits for selected patients exceeding grade BCLC 0-A. In this regard, the widening of indications for PH in official treatment guidelines is needed, such as those found in the Hong Kong Liver Cancer Staging System, which nevertheless requires more sophisticated and comprehensive evidence in order to be adopted. (37) In the present systematic review and meta-analysis based on 18 trials (one RCT, five PSM NRCTs, and 12 NRCTs) with 5,986 patients, we demonstrate that BCLC stage B/C HCC patients who underwent PH had a 40% decrease in OS rates and greater than 2.5-fold increase in the 5-year survival rate in comparison to TACE. In addition, the survival outcomes in pooled RCTs and PSM NRCTs were consistent with those of all studies. Last, this survival benefit persisted across subgroups, sensitivity, and metaregression analyses and did not appear to be significantly influenced by BCLC stage and baseline characteristics of the trials included in our study.
BCLC stage B patients represent an enormous unmet need population falling between guidelinedriven therapeutic strategies and empirically based potential treatments in real-world practice. Because multiple TACE courses are associated with repeated ischemic injury to nontumor liver parenchyma and adverse events, which may worsen patients' survival, the current recommendations for TACE do not benefit all BCLC stage B patients. Although some methodological criticisms remain, a recent Cochrane report has shown that there is no evidence supporting the beneficial effect of TACE (or transarterial embolization) on survival or tumor growth (nine RCTs with 645 participants; TACE vs. controls; HR, 0.88; 95% CI, 0.71-1.10; P 5 0.27). (38) In this perspective, an expert panel from the 2012 International Liver Congress hosted by the EASL suggests that intermediatestage HCC (BCLC stage B) comprises a highly heterogeneous patient population. (39) They proposed a further subclassification of intermediate HCC into four groups (B1-B4) using key parameters related to tumor burden and liver function (e.g., CTP class, PS, and tumor size and number). The researchers recommended that B1 patients (CTP score 5-7, beyond Milan staging but within up-to-7 criteria, PS 0, and without PVT) or selected B4 patients (CTP scores 8-9, beyond Milan staging but within up-to-7 criteria, PS 0, and without PVT) be treated by LT. (39) Even for expert panels, however, PH is still restricted and underestimated as a treatment modality for intermediate-stage HCC. In the present analysis, nine trials (one PSM NRCT and eight NRCTs) including 3,457 BCLC B patients, a significant survival benefit was shown for PH (HR, 0.53; 1-year survival rate for PH vs. TACE: 84% vs. 68%; 5-year survival rate for PH vs. TACE: 45% vs. 23%, respectively). In particular, a higher baseline proportion of CTP A patients tended to show more survival benefit for PH over TACE (80% of CTP A proportion vs. <80% of CTP A patients; HR, 0.44 vs. 0.65, respectively). Therefore, PH should be considered a therapeutic option tailored to a carefully selected group of BCLC stage B HCC patients with well-preserved liver function.
The survival outcome for advanced-stage HCC patients (BCLC stage C) remains poor even for sorafenib-treated patients (sorafenib vs. controls; median survival 5 9.7 vs. 7.0 months, respectively). (40) Although the role of surgery in this patient group was insufficiently defined, an increasing number of studies have attempted aggressive surgical resection to remove all tumor tissue detected during imaging studies in patients with well-preserved liver function. Previous reports have suggested that PH is a safe and effective treatment if tumor thrombus is confined to the first (PVT type I) or the second (PVT type II) branch of the main portal vein (3-and 5-year survival rates ranging from 17% to 54% and from 10% to 38%, respectively). (22, (24) (25) (26) 31) Conversely, when the tumor thrombus extends into the main portal vein trunk (PVT type III-IV), the 3-and 5-year survival rates decreased (range, 4%-14% and 0%-5%, respectively). (22, (24) (25) (26) 31) Additionally, patients who underwent hepatic resection for hepatic vein tumor thrombosis (HVT) also showed favorable median survival of 15.6 months and a 29% 3-year survival rate. (28, 41) Overall, PH for selected BCLC stage C patients with major vascular invasion showed a favorable median survival (range, 9-33 months) and perioperative mortality (range, 0%-5%). (22, (24) (25) (26) 28, 31, 41) In this respect, a recent consensus meeting from the 5th Asia-Pacific Primary Liver Cancer Expert (APPLE 2014) reported that all 13 experts agreed that portal venous invasion and hepatic venous invasion are not absolute contraindications for the surgical resection of HCC. (42) According to the consensus, surgical resection can be performed for HCCs involving the ipsilateral portal vein (Grade B recommendation). (42) In our study, nine trials (three PSM NRCTs and six NRCTs) involving 3,051 BCLC stage C patients showed significantly better OS for PH than TACE (HR, 0.67; 1-year survival rate for PH vs. TACE, 62% vs. 45%; 5-year survival rate for PH vs. TACE, 20% vs. 8.0%, respectively).
However, the results of our study should be interpreted with caution. Although most centers still offer TACE or PH to BCLC stage C HCC patients, current general standard practice recommended by international guidelines for BCLC stage C HCC patients is systemic therapy with molecular targeting agents. Moreover, there has been no reliable study comparing PH or TACE with systemic target therapy for BCLC stage C HCC patients. Therefore, improvement of survival with PH over TACE in this study does not necessarily mean that surgical resection could be better than systemic target therapy in BCLC stage C HCC patients. Nevertheless, these results may provide evidence supporting the use of PH even in BCLC stage C patients. Considerations in favor of PH for this expanding population need to be further refined.
There have been several meta-analyses to date. Tian et al. reported the first meta-analysis comparing survival outcomes for patients receiving PH or TACE in BCLC A/B HCC. (43) They analyzed 11 trials (6,297 patients) and showed similar 5-year survival rates for PH and TACE (OR, 0.77; 95% CI, 0.59-1.01; P 5 0.06). Because of insufficient data, however, the comparison of the treatment effect in BCLC stage B patients was limited in the study. (43) (45) They showed a survival benefit for PH compared to TACE in patients beyond BCLC stage A (17 trials; HR, 0.60; 95% CI, 0.51-0.69; P < 0.00001), BCLC stage B alone (three trials; HR, 0.48; 95% CI, 0.25-0.90; P 5 0.02), and HCC with PVT (five trials; HR, 0.78; 95% CI: 0.68-0.91; P 5 0.0009) patients. However, they included data from conference abstracts, and some studies overlapped from identical centers. (45) To our knowledge, the present study is the largest meta-analysis including high-quality studies to date with sophisticated subgroup and sensitivity analyses providing extended evidence regarding the above issues.
The limitations to our study should be considered. First, most evidence for the feasibility of PH with respect to the current guidelines are based on NRCTs. Because of a number of technical and ethical considerations, only one prospective RCT was available. (10) Therefore, we used a two-step stratified analysis to calculate survival outcomes, and found that those from the pooled RCT 1 PSM NRCT were consistent with outcomes from the all the studies combined. Further well-designed, randomized studies evaluating the benefits of PH as an extended indication are required. Second, a substantial degree of heterogeneity was found.
